Gene Biotherapeutics Inc. (CRXM)
Stock Price:
$0.0788 USD
0.0101 (14.70%)
Updated Aug 7, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
1.13M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-3.07M |
| Shares Out |
14.37M |
| EPS (ttm) |
-0.29 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$0.0788 |
| Previous Close |
$0.0687 |
| Change ($) |
0.0101 |
| Change (%) |
14.70% |
| Day's Open |
0.0690 |
| Day's Range |
0.0680 - 0.0788 |
| Day's Volume |
236,570 |
| 52-Week Range |
0.0204 - 0.1900 |
More Stats
| Market Cap |
1.13M |
| Enterprise Value |
956,304 |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
14.37M |
| Float |
12.78M |
| EPS (basic) |
-0.3 |
| EPS (diluted) |
-0.29 |
| FCF / Share |
-0.18 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
150,251 |
| Short Ratio |
1.03 |
| Short % of Float |
2.47% |
| Beta |
1.66 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.36 |
| Revenue |
n/a |
| Operating Income |
-3.07M |
| Net Income |
-3.07M |
| Free Cash Flow |
-2.55M |
| Net Cash |
176,367 |
| Net Cash / Share |
0.01 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-758.60% |
| ROE |
n/a |
| ROIC |
68.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
2.00
Current: $0.0788
High
2.00
Target: 2.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|
| Revenue | - | - | - | 0.11 | 0.06 | - | 0.24 | 0.44 | 0.42 | 0.45 |
| Revenue Growth | - | - | - | 83.81% | - | - | -45.05% | 6.72% | -6.51% | - |
| Gross Profit | - | - | - | 0.04 | 0.01 | - | 0.24 | 0.44 | 0.42 | 0.45 |
| Operating Income | -2.84 | -3.11 | -3.58 | -6.91 | -8.29 | -7.42 | -6.77 | -8.71 | -17.15 | -17.44 |
| Net Income | -2.92 | -3.70 | -5.51 | -8.91 | -8.32 | -7.13 | -4.74 | -11.68 | -24.60 | -25.32 |
| Shares Outstanding | 13.33 | 12.86 | 11.12 | 7.00 | 5.92 | 4.25 | 3.69 | 2.45 | 2.25 | 1.97 |
| Earnings Per Share | -0.28 | -0.34 | -0.50 | -1.33 | -1.41 | -1.60 | -1.20 | -4.80 | -11.00 | -12.80 |
| Operating Cash Flow | -2.02 | -1.05 | -2.62 | -6.03 | -9.21 | -7.67 | -7.41 | -11.61 | -16.61 | -21.36 |
| Capital Expenditures | -0.17 | - | - | -0.02 | -0.02 | - | -0.05 | - | -0.68 | -1.23 |
| Free Cash Flow | -2.20 | -1.05 | -2.62 | -6.05 | -9.23 | -7.68 | -7.47 | -11.61 | -17.30 | -22.58 |
| Cash & Equivalents | 0.93 | 0.02 | 0.22 | 0.02 | 2.33 | 4.92 | 8.07 | 4.79 | 1.50 | 8.32 |
| Total Debt | - | - | - | - | - | - | - | - | 4.04 | 4.72 |
| Net Cash / Debt | 0.93 | 0.02 | 0.22 | 0.02 | 2.33 | 4.92 | 8.07 | 4.79 | -2.53 | 3.59 |
| Assets | 1.11 | 0.04 | 0.75 | 2.79 | 7.81 | 7.50 | 9.51 | 5.48 | 10.30 | 16.93 |
| Liabilities | 4.40 | 3.83 | 2.43 | 1.60 | 1.44 | 1.42 | 2.08 | 7.63 | 11.05 | 8.50 |
| Book Value | -3.14 | - | -1.68 | 1.19 | 6.37 | 6.08 | 7.43 | -2.15 | -0.75 | 8.43 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Gene Biotherapeutics Inc. |
| Country |
United States |
| Employees |
6 |
| CEO |
Christopher J. Reinhard |
Stock Information
| Ticker Symbol |
CRXM |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: CRXM |
Description
Gene Biotherapeutics, Inc. manages a portfolio of medical technologies in the United States. It focuses on acquiring and developing gene-based therapeutics. The company, through its subsidiary, Angionetics, Inc., focuses on the clinical advancement and commercialization of Generx, an interventional cardiology, angiogenic gene therapy Phase 3 product candidate designed for the potential treatment of patients with refractory angina due to advanced coronary artery disease. It also holds royalties on the commercialization of Excellagen technology platform for advanced wound care in Eurasian countries. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was founded in 2003 and is headquartered in San Diego, California.